Last Updated on December 25, 2024 by The Health Master
USFDA
Biocon, a leading global biopharmaceutical company, has recently received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status from the US Food and Drug Administration (USFDA).
This follows a surveillance inspection conducted at the company’s API facility (Site 2) in Bengaluru, Karnataka, between September 23 and 27, 2024.
What is a VAI Status?
A VAI status indicates that while the facility meets certain regulatory requirements, there are areas that require corrective action.
However, it’s important to note that this does not necessarily lead to an official action from the USFDA.
Biocon has acknowledged the findings and will be taking steps to address the issues highlighted in the EIR.
Impact on Biocon’s Operations
While the VAI status may raise some concerns, it’s crucial to understand that it doesn’t automatically halt operations or shipments.
Biocon will continue to work closely with the USFDA to resolve the identified issues and ensure compliance with regulatory standards.
Key Takeaways
- Biocon’s Bengaluru API facility received a VAI status from the USFDA.
- The VAI indicates areas requiring corrective action but doesn’t necessitate an official USFDA action.
- Biocon will work to address the issues and maintain regulatory compliance.
- The long-term impact on Biocon’s operations and share price remains to be seen.
-
What is a VAI Status?
A VAI status indicates that while the facility meets certain regulatory requirements, there are areas that require corrective action. However, it’s important to note that this does not necessarily lead to an official action from the USFDA.
-
What is an EIR?
An EIR is a formal report issued by the USFDA after inspecting a pharmaceutical facility. It outlines any observations or findings related to regulatory compliance.
-
What does VAI mean for Biocon’s future?
A VAI status is not uncommon in the pharmaceutical industry. Biocon is committed to addressing the issues and maintaining high quality standards.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
USFDA issued Form 483 with two observations to Aurobindo for API plant
NPPA fixed retail price of 65 formulations: December 2024
Key Notes on Revised Schedule M: Point No. 10 – Self Inspection
Medical Device recall: USFDA classifies recall of these catheters as ‘most serious’
NPPA: New Strategy to Curb Drug Price Hikes
Pharmexcil 2024 Elections: New Leadership for India’s Pharmaceutical Industry
Key Notes on Revised Schedule M: Point No. 9 – Production under Loan License
Drug recall: 1,394 batches of drugs recalled in 2023-24 due to quality issues
Chemists want Ayurvedic Medicine Under FDA Scrutiny
USFDA issues warning letter to Indoco Remedies for Goa facility
Bulk drug import from China continues to rise in 5 years
Stay action against Pharma units manufacturing Nutraceuticals: High Court
NPPA fixed retail price of 7 formulations: December 2024
Revised Schedule M: Industry seeks balance between Quality and Viability
FDA Karnataka enters a New Era of Food and Drug Safety
Key Notes on Revised Schedule M: Point No. 13 – Equipment
GST Penalty of Rs. 1.11 Crore on Cipla
FSSAI regulations on use of Methylcobalamin in Supplements
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
